|
rs12998806
|
|
|
0.710 |
GeneticVariation |
BEFREE |
In addition, we confirmed SNP rs10069690 was the best indicator for ER-negative breast cancer at 5p15.33 (OR = 1.30; P = 2.4 × 10 − 10) and identified rs12998806 as the best indicator for ER-positive breast cancer at 2q35 (OR = 1.34; P = 2.2 × 10 − 8) for women of African ancestry.
|
28171663 |
2016 |
|
rs11251942
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study of germline variants and breast cancer-specific mortality.
|
30787463 |
2019 |
|
rs12938141
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study of germline variants and breast cancer-specific mortality.
|
30787463 |
2019 |
|
rs140538758
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study of germline variants and breast cancer-specific mortality.
|
30787463 |
2019 |
|
rs4717568
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study of germline variants and breast cancer-specific mortality.
|
30787463 |
2019 |
|
rs587150
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study of germline variants and breast cancer-specific mortality.
|
30787463 |
2019 |
|
rs62235635
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study of germline variants and breast cancer-specific mortality.
|
30787463 |
2019 |
|
rs6938753
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study of germline variants and breast cancer-specific mortality.
|
30787463 |
2019 |
|
rs7082321
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study of germline variants and breast cancer-specific mortality.
|
30787463 |
2019 |
|
rs73370840
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study of germline variants and breast cancer-specific mortality.
|
30787463 |
2019 |
|
rs79116769
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study of germline variants and breast cancer-specific mortality.
|
30787463 |
2019 |
|
rs10941679
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation.
|
27640304 |
2016 |
|
rs10941679
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In addition, we find both rs4415084 and rs10941679 conferred significantly greater risks of ER-positive breast cancer than of ER-negative tumors.
|
24039999 |
2013 |
|
rs700518
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.
|
23643682 |
2013 |
|
rs700518
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Because AI use results in severe estrogen deficiency that may lead to changes in body composition, the aim of this study was to determine the effect of the rs700518 polymorphism in the CYP19A1 gene on the changes in body composition among postmenopausal women who were treated with AIs for ER+ breast cancer.
|
26049585 |
2015 |
|
rs865686
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We recently identified a novel susceptibility variant, rs865686, for estrogen-receptor positive breast cancer at 9q31.2.
|
25652398 |
2015 |
|
rs865686
|
|
|
0.020 |
GeneticVariation |
BEFREE |
9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium.
|
22859399 |
2012 |
|
rs10069690
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In addition, we confirmed SNP rs10069690 was the best indicator for ER-negative breast cancer at 5p15.33 (OR = 1.30; P = 2.4 × 10 − 10) and identified rs12998806 as the best indicator for ER-positive breast cancer at 2q35 (OR = 1.34; P = 2.2 × 10 − 8) for women of African ancestry.
|
28171663 |
2016 |
|
rs1042522
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women.
|
15183535 |
2004 |
|
rs10771399
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We identified three new breast cancer risk loci at 12p11 (rs10771399; P = 2.7 × 10(-35)), 12q24 (rs1292011; P = 4.3 × 10(-19)) and 21q21 (rs2823093; P = 1.1 × 10(-12)). rs10771399 was associated with similar relative risks for both estrogen receptor (ER)-negative and ER-positive breast cancer, whereas the other two loci were associated only with ER-positive disease.
|
22267197 |
2012 |
|
rs10822013
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When stratified based on breast cancer subtype, our analyses revealed that three SNPs (rs981782, rs10759243 and rs704010) correlated with ER+ breast cancer, while another three (rs4973768, rs1432679 and rs10822013) correlated with ER- breast cancer.
|
27863437 |
2016 |
|
rs1131691014
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women.
|
15183535 |
2004 |
|
rs121434592
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Both assays are employed at centralized testing laboratories operating according to quality standards for prospective identification of the AKT1 E17K mutation in ER+ breast cancer patients in the context of a clinical trial evaluating the AKT inhibitor AZD5363 in combination with endocrine (fulvestrant) therapy.
|
28472036 |
2017 |
|
rs12443621
|
|
|
0.010 |
GeneticVariation |
BEFREE |
However, rs12443621 AG/GG genotypes were significantly associated with increased risk of ER positive breast cancer (OR = 1.38, 95% CI = 1.01-1.88), compared with homozygote AA.
|
20213080 |
2010 |
|
rs1292011
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We identified three new breast cancer risk loci at 12p11 (rs10771399; P = 2.7 × 10(-35)), 12q24 (rs1292011; P = 4.3 × 10(-19)) and 21q21 (rs2823093; P = 1.1 × 10(-12)). rs10771399 was associated with similar relative risks for both estrogen receptor (ER)-negative and ER-positive breast cancer, whereas the other two loci were associated only with ER-positive disease.
|
22267197 |
2012 |